# IKT catalysts: Inhibikase Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ikt/catalysts

> Inhibikase Therapeutics, Inc. (IKT) has 5 upcoming catalysts. The next is the imatinib interim data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IKT?

Inhibikase Therapeutics, Inc. (IKT) has 5 upcoming catalysts. The next is the imatinib interim data readout, 1H 2027. Press release filed with the SEC (EX-99): "An interim safety readout for Part A of the Phase 3 IMPROVE-PAH study (n=50) is planned for the first half of 2027." [Calendar and source filings](https://sec-api.dev/companies/ikt/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-455560, https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/d95716dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/companies/ikt/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Inhibikase Therapeutics, Inc. |
| Ticker | IKT (Nasdaq) |
| SEC CIK | 1750149 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/ikt |

## Cash runway

Cash $178.8M as of 2025-12-31; quarterly burn $7.5M; about 71.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-126371).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [Imatinib topline data readout](https://sec-api.dev/pdufa/imatinib) | IKT |  | completed, missed | "For example, in June 2024, Aerovate Therapeutics developing an inhaled imatinib product candidate for PAH announced topline Phase 2b clinical trial results indicating the trial did not meet its primary endpoint for improvement in pulmonary vascular resistance versus placebo." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm)) |
| October 6, 2024 | [Risvodetinib trial start](https://sec-api.dev/pdufa/risvodetinib) | IKT |  | completed | "In 2023, we initiated the Phase 2 201 trial ("201 Trial") for risvodetinib (IkT-148009) as a treatment for Parkinson's disease and completed that trial on October 6, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm)) |
| Nov 2024 | [Imatinib trial start](https://sec-api.dev/pdufa/imatinib) | IKT |  | completed | "While in November 2024, the Company received authorization for its Phase 2 trial (702 trial) for IKT-001 for PAH, in addition to our already commenced Phase 1 and Phase 2 clinical trials and our two-part dose finding/dose equivalence study for IKT-001, we could encounter problems that could halt our planned clinical trials or require us to repeat such clinical trials." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm)) |
| March 27, 2025 | [Inhibikase Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ikt/catalysts) | IKT |  | completed | "Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312525065511/d943685dex991.htm)) |
| May 14, 2025 | [Inhibikase Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ikt/catalysts) | IKT |  | completed | "May 14, 2025  Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (PAH), today reported financial results for the quarter ended March 31, 2025 and highlighted recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312525119939/d940084dex991.htm)) |
| August 14, 2025 | [Inhibikase Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ikt/catalysts) | IKT |  | completed | "August 14, 2025  Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (PAH), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312525180889/d946023dex991.htm)) |
| Q4 2025 | [Imatinib trial start](https://sec-api.dev/pdufa/imatinib) | IKT |  | scheduled | "Initiation of IKT's Phase 3 Study in PAH Projected Events st Expected 1 Site Activation in Phase 3 IMPROVE-PAH Study (IKT- ✓ 1H 2024 FDA Pre-IND for IKT-001 in PAH Q4 2025 / Q1 001 for Measuring Pulmonary Vascular Resistance and Outcome" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312525289768/d20255dex991.htm)) |
| November 14, 2025 | [Inhibikase Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ikt/catalysts) | IKT |  | completed | "November 14, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312525283075/d93377dex991.htm)) |
| March 26, 2026 | [Inhibikase Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ikt/catalysts) | IKT |  | completed | ""Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the year ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126322/d119328dex991.htm)) |
| May 12, 2026 | [Imatinib earnings report](https://sec-api.dev/pdufa/imatinib) | IKT |  | completed | ""Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended March 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/d119997dex991.htm)) |
| August 11, 2026 | [Imatinib earnings report](https://sec-api.dev/pdufa/imatinib) | IKT |  | completed | ""Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/d134059dex991.htm)) |
| November 10, 2026 | [Imatinib earnings report](https://sec-api.dev/pdufa/imatinib) | IKT |  | completed | ""Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended September 30, 2026, and highlighted recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/d95716dex991.htm)) |
| 1H 2027 | [Imatinib interim data readout](https://sec-api.dev/pdufa/imatinib) | IKT |  | scheduled | "An interim safety readout for Part A of the Phase 3 IMPROVE-PAH study (n=50) is planned for the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/d95716dex991.htm)) |
| June 2029 | [IKT-001 primary completion](https://sec-api.dev/pdufa/ikt-001) | IKT | Pulmonary Arterial Hypertension | scheduled | "NCT07365332 (An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Inhibikase Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365332)) |
| Jun to Sep 2029 | [IKT-001 topline data readout](https://sec-api.dev/pdufa/ikt-001) | IKT | Pulmonary Arterial Hypertension | scheduled | "NCT07365332 (An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Inhibikase Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365332)) |
| Jun to Sep 2030 | [IKT-001 topline data readout](https://sec-api.dev/pdufa/ikt-001) | IKT | Pulmonary Arterial Hypertension (PAH) | scheduled | "NCT07632898 (Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor Inhibikase Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07632898)) |
| June 2030 | [IKT-001 primary completion](https://sec-api.dev/pdufa/ikt-001) | IKT | Pulmonary Arterial Hypertension (PAH) | scheduled | "NCT07632898 (Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor Inhibikase Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07632898)) |

## Drugs

- [IKT-001](https://sec-api.dev/pdufa/ikt-001): Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
- [Imatinib](https://sec-api.dev/pdufa/imatinib): 
- [Risvodetinib](https://sec-api.dev/pdufa/risvodetinib): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ikt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IKT catalysts: Inhibikase Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ikt/catalysts

```bibtex
@misc{secapidev_companies_ikt_catalysts_20261116,
  title        = {IKT catalysts: Inhibikase Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ikt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ikt_catalysts_20261116","title":"IKT catalysts: Inhibikase Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ikt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
